CytoMed Therapeutics GDTC Cash Flow Statement (2021-2026)

NASDAQ GDTC
$0.90 +0.06 (+6.75%)
At close: Oct 1, 2026 · 4:00 PM EDT
Reported Financials

CytoMed Therapeutics Quarterly Cash Flow Statement

Periods 6 quarters
Latest Jun 2026

CytoMed Therapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 6 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2021 Dec2022 Jun2023 Jun2024 Jun2025 Jun2026
Operating Activities
Depreciation and Depletion 0.15M0.12M0.08M
Share-based Compensation 0.30M0.35M0.42M0.46M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.00M321.00321.00
Depreciation & Amortization (CF)Depreciation & Amortization 0.15M0.12M0.08M
Investing Activities
Change in Acquisitions & Divestments -5.44M-0.48M0.27M
Financing Activities
Change in Capital Stock
Shares Issued 0.70M0.35M

CytoMed Therapeutics Cash Flow Statement API

Pull CytoMed Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=GDTC&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY